Medical Marijuana Program
for Wallingford, CT & the Surrounding Areas

Looking for a CT medical marijuana card for a variety of conditions?

Park Avenue Medical certifies patients for medical marijuana cards based on criteria set by the state of Connecticut. At Park Avenue Medical, we stay up to date with all the current medications and treatments. That’s why we started certifying patients in Wallingford, North Haven, Middletown, Cheshire, Meriden, CT, and the surrounding areas for medical marijuana cards years ago. The evidence has shown its efficacy for treating PTSD, anxiety, and chronic pain disorders, among many other conditions. Our patients often use medical marijuana in conjunction with other treatment methods to provide a holistic approach to health. Our patients have found success for a variety of ailments with medical marijuana, and we love helping them with their journey.

To initiate the process, we first review the patient’s medical records (free of charge) to determine if they qualify for medical marijuana. Upon approval, the patient comes for an appointment where we educate them about the policies surrounding medical marijuana. Patients come in yearly for renewal of their medical card. The pharmacists who work at the dispensaries around Connecticut have ample knowledge regarding medical marijuana, and they can answer specific questions after you get your medical marijuana card.

For more information about the medical marijuana program or to see if you would benefit from medical marijuana, we encourage you to contact us today!

When initially getting certified and/or every time you renew, you’ll need the following documents:

● Identification - driver's license, passport, state ID, etc.

● Proof of residence - piece of mail, bank statement, bills, etc.

● Letter from the medical provider diagnosing you with the condition treatable with medical marijuana

Qualifying diagnoses for adults:

● Cancer (Effective 2012)

● Glaucoma (Effective 2012)

● Positive Status for Human Immunodeficiency Virus or Acquired Immune Deficiency Syndrome (Effective 2012)

● Parkinson's Disease (Effective 2012)

● Multiple Sclerosis (Effective 2012)

● Damage to the Nervous Tissue of the Spinal Cord with Objective Neurological Indication of Intractable Spasticity (Effective 2012)

● Epilepsy (Effective 2012)

● Cachexia (Effective 2012)

● Wasting Syndrome (Effective 2012)

● Crohn's Disease (Effective 2012)

● Post-Traumatic Stress Disorder (Effective 2012)

● Sickle Cell Disease (Effective 2016)*

● Post Laminectomy Syndrome with Chronic Radiculopathy (Effective 2016)*

● Severe Psoriasis and Psoriatic Arthritis (Effective 2016)*

● Amyotrophic Lateral Sclerosis (Effective 2016)*

● Ulcerative Colitis (Effective 2016)*

● Complex Regional Pain Syndrome, Type 1 and Type II (Effective 2016)*

● Cerebral Palsy (Effective 2016)

● Cystic Fibrosis (Effective 2016)

● Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)

● Terminal Illness Requiring End-Of-Life Care (Effective 2016)

● Uncontrolled Intractable Seizure Disorder (Effective 2016)

● Spasticity or Neuropathic Pain Associated with Fibromyalgia (Effective 2018)*

● Severe Rheumatoid Arthritis (Effective 2018)*

● Post Herpetic Neuralgia (Effective 2018)*

● Hydrocephalus with Intractable Headache (Effective 2018)*

● Intractable Headache Syndromes (Effective 2018)*

● Neuropathic Facial Pain (Effective 2018)*

● Muscular Dystrophy (Effective 2018)*

● Osteogenesis Imperfecta (Effective 2018)*

● Chronic Neuropathic Pain Associated with Degenerative Spinal Disorders (Effective 2018)*

● Interstitial Cystitis (Effective 2019)*

● MALS Syndrome (Median Arcuate Ligament Syndrome) (Effective 2019)*

● Vulvodynia and Vulvar Burning (Effective 2019)*

● Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*

● Tourette Syndrome (Effective 2019)*

● Chronic Pain of at least 6 months duration associated with a specified underlying chronic condition refractory to other treatment intervention (Effective 2020)*

● Ehlers-Danlos Syndrome Associated with Chronic Pain (Effective 2020)*

● Chronic Pancreatitis (Effective 2021)*

● Movement disorders associated with Huntington Disease (Effective 2021)^

Qualifying diagnoses for children:

● Cerebral Palsy (Effective 2016)

● Cystic Fibrosis (Effective 2016)

● Irreversible Spinal Cord Injury with Objective Neurological Indication of Intractable Spasticity (Effective 2016)

● Severe Epilepsy (Effective 2016)

● Terminal Illness Requiring End-Of-Life Care (Effective 2016)

● Uncontrolled Intractable Seizure Disorder (Effective 2016)

● Muscular Dystrophy (Effective 2018)*

● Osteogenesis Imperfecta (Effective 2018)*

● Intractable Neuropathic Pain that Is Unresponsive to Standard Medical Treatments (Effective 2019)*

● Tourette Syndrome for patients who have failed standard medical treatment (Effective 2019)*

● Chronic Pancreatitis for patients whose pain is recalcitrant to standard medical management (Effective 2021)*

* Conditions were approved by the Regulation Review Committee via the recommendation of the Board of Physicians and Commissioner of Consumer Protection.

^ Condition was approved, pursuant to the Public Act 21-1 the Responsible and Equitable Regulations of Adult-Use Cannabis Act, upon publication on the Department of Consumer Protections website.